CT texture features of lung adenocarcinoma with HER2 mutation

肺腺癌HER2突变的CT纹理特征

阅读:2

Abstract

BACKGROUND: Mutations in human receptor tyrosine kinase epidermal growth factor receptor-2 (HER2) are rare. This study aimed to investigate the clinical characteristics and computed tomography (CT) texture features of lung adenocarcinoma (LUAD) patients with HER2 mutation. METHODS: This study included 933 LUAD patients from January 2018 to December 2023 and classified their CT textures accordingly. RESULTS: The data indicated that the incidence of HER2 mutation was higher in younger LUAD patients than in elder patients [7.5% (31/413) vs. 1.5% (8/520), p < 0.0001] and was associated with never-smokers [0% (0/78) vs. 4.6% (39/855), p = 0.03]. In this study, the tumors were categorized based on their diameter into T1a and ≥ T1b. The data revealed that HER2 mutation was more frequent in T1a than in ≥ T1b [11.0% (23/210) vs. 2.2% (16/723), p < 0.0001]. Furthermore, non-pSD was more common than pSD in LUAD with HER2 mutation than in LUAD with HER2 wild type [82.1% (31/39) vs.17.9% (7/39), p = 0.01]. Moreover, the size of pGGO (0.94 ± 0.29 cm vs. 1.24 ± 0.39 cm, p = 0.0009), mGGO (0.86 ± 0.39 cm vs. 1.5 ± 0.77 cm, p < 0.0001) and pSD (1.75 ± 0.81 cm vs. 2.5 ± 1.4 cm, p < 0.05) in LUAD patients with HER2 mutation was smaller than those with HER2 wild type patients. In addition, when LUADs with HER2 wild type transformed from pGGO to mGGO, their sizes increased significantly (1.50 ± 0.77 cm vs. 1.24 ± 0.39 cm). It was also observed that the incidence of LUAD with HER2 mutation of ≤ 1 cm was significantly more than that of > 1 cm comparing to that in LUAD with HER2 wild type [14.8% (12/81) vs. 1.7% (3/173), p < 0.0001]. CONCLUSION: This study indicated that the incidence of HER2 mutation was higher in younger and never-smoking LUAD patients. Furthermore, the growth of LUAD with HER2 mutation was slower than that of those with HER2 wild type. Moreover, most LUAD with HER2 mutation changed into pSD after > 1 cm.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。